Description

Hepatofalk CAS NO 77573-68-3 is a high-purity pharmaceutical intermediate and active ingredient, specifically a complex of ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA). This compound is critical for the development and production of advanced hepatoprotective and choleretic medications. It is primarily required by pharmaceutical manufacturers and research institutions focused on liver disease therapeutics, metabolic studies, and bile acid research.

Application

• Pharmaceutical Active Ingredient: Primary use in the formulation of hepatoprotective drugs for treating cholestatic liver diseases, primary biliary cholangitis (PBC), and gallstone dissolution.
• Research & Development: Serves as a key reference standard and biochemical tool in metabolic pathway studies, hepatotoxicity assays, and bile acid metabolism research.
• API Synthesis: Used as a critical starting material or intermediate in the multi-step synthesis of more complex therapeutic agents targeting liver and gastrointestinal disorders.
• Clinical Studies: Employed in the preparation of clinical trial materials for evaluating new treatments for chronic liver conditions.
• Biochemical Reagent: Utilized in in-vitro diagnostic applications and cell culture studies to investigate liver function and cellular responses.

Basic Information

Product Name	Hepatofalk
CAS No.	77573-68-3
Molecular Formula	C24H40O4 • C24H40O4
Molecular Weight	392.57 (UDCA) + 392.57 (CDCA)
Synonyms	Ursodeoxycholic Acid and Chenodeoxycholic Acid Complex; UDCA-CDCA Complex; Ursochenodeoxycholate; Cholestatin; Cholestifalk; Hepafalk; Bilifalk; 3α,7β-Dihydroxy-5β-cholan-24-oic Acid / 3α,7α-Dihydroxy-5β-cholan-24-oic Acid Mixture
EINECS	Contact for details

Quality Control

Our Hepatofalk is manufactured under strict quality management systems. Each batch is subjected to rigorous analytical testing, including identification, assay, and impurity profiling, to ensure it meets the stringent requirements for pharmaceutical use. We provide comprehensive Certificates of Analysis (COA) that detail compliance with relevant pharmacopeial standards (such as USP/EP monographs for the individual components) and customer-specific specifications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). The product is hygroscopic (moisture-sensitive) and should be handled under dry conditions to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.5% (Total of UDCA and CDCA)
Ratio (UDCA:CDCA)	As per customer requirement
Related Substances (HPLC)	Total impurities ≤ 1.0%
Individual Unknown Impurity	≤ 0.10%
Loss on Drying	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.